Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin with Paclitaxel and Carboplatin in Advanced Ovarian Cancer
NCT00391118Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2006
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Enzastaurin Arm with Placebo Arm (2 arms). Primary endpoint: Progression-Free Survival up to 28.6 months. Started Nov 2006; status: completed.
02
Drugs
enzastaurin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00391118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391118.